Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition From Oral Atypical Antipsychotics to Cobenfy™ (Xanomeline and Trospium Chloride)

Key Takeaways

• 86% of participants completed 8‑week switch study.
• No discontinuations due to lack of efficacy observed.
• PANSS scores decreased modestly in both fast and slow switches.
• TEAE incidence ~49% with no serious adverse events.
• Faster 2‑week cross‑titration comparable to 4‑week protocol.

Summary

Bristol Myers Squibb reported Phase 4 data showing that adults with schizophrenia can switch from oral atypical antipsychotics to Cobenfy (xanomeline‑trospium) without loss of symptom control. In an 8‑week open‑label trial, 86% of 105 patients completed the study, and mean PANSS scores stayed below baseline regardless of a 2‑week or 4‑week cross‑titration schedule. No participants discontinued Cobenfy due to lack of efficacy, and safety was consistent with earlier studies, with about half experiencing non‑serious adverse events. The results were presented at the 2026 SIRS Congress in Florence.

Pulse Analysis

Switching antipsychotic regimens has long been a clinical challenge, with physicians wary of destabilizing patients during cross‑titration. Traditional atypical agents lack clear guidance on optimal tapering periods, creating uncertainty that can delay treatment changes. Cobenfy, the first schizophrenia drug in decades to target muscarinic receptors, promises a different therapeutic pathway, but clinicians needed real‑world data on how to transition patients safely. The recent Phase 4 trial fills that gap by directly comparing two practical titration schedules, offering a data‑driven roadmap for everyday practice.

The open‑label study enrolled 105 adults stabilized on atypical antipsychotics and randomized them to either a rapid two‑week or a slower four‑week taper while up‑titrating Cobenfy to 125/30 mg twice daily. Across both arms, mean PANSS total scores fell by 3‑4 points, and CGI‑S scores improved modestly, indicating maintained or slightly better symptom control. Completion rates exceeded 85%, and no patient stopped Cobenfy for inefficacy. Adverse events occurred in roughly half the cohort, mirroring prior EMERGENT trial rates, and none were serious, underscoring a tolerable safety profile during the switch.

For the schizophrenia market, these results could accelerate Cobenfy adoption, especially in settings where rapid medication changes are necessary due to side‑effect burdens or insurance constraints. The comparable outcomes between fast and slow cross‑titration give prescribers flexibility to tailor switches to individual patient needs without compromising efficacy. As payers and providers seek cost‑effective, evidence‑based treatment pathways, the trial’s data may support broader formulary inclusion and encourage further research into muscarinic‑based therapies, potentially reshaping the therapeutic landscape for this chronic disorder.